Lack of immunoediting in murine pancreatic cancer reversed with neoantigen-Reference-Cited by-同舟云学术

Lack of immunoediting in murine pancreatic cancer reversed with neoantigen

Published:2016-09-08 Issue:14 Volume:1 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Evans Rebecca A.,Diamond Mark S.,Rech Andrew J.,Chao Timothy,Richardson Max W.,Lin Jeffrey H.,Bajor David L.,Byrne Katelyn T.,Stanger Ben Z.,Riley James L.,Markosyan Nune,Winograd Rafael,Vonderheide Robert H.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference46 articles.

1. The future of immune checkpoint therapy

2. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

3. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

4. Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr Virus Protein LMP1 in a Mouse Model

5. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors;International Immunopharmacology;2024-09

2. Unraveling spontaneous humoral immune responses against human cancer: a road to novel immunotherapies;Journal of Leukocyte Biology;2024-08-27

3. Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer;Science;2024-06-28

4. Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond;Molecular Cancer;2024-06-26

5. Current and future immunotherapeutic approaches in pancreatic cancer treatment;Journal of Hematology & Oncology;2024-06-04